Relative potencies of flutamide and 'Casodex'

Endocrine-Related Cancer

Volumn 4, Issue 2, 1997, Pages 197-202

  Furr, B J A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; GONADORELIN AGONIST; HYDROXYFLUTAMIDE; TESTOSTERONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; MALE; NONHUMAN; PROSTATE CANCER; RAT;

EID: 0030854929     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0040197     Document Type: Article

References (34)

1. Asade RH, Prizont L, Ponce Muino J & Tessler J 1991 Steady state hydroxyflutamide plasma levels after the administration of two dosage forms of flutamide. Cancer Chemotherapeutics and Pharmacology 27 401-405.
2. 3H] Cortisol binding to plasma proteins. Journal of Steroid Biochemistry 33 251-255.
3. Belanger A, Giasson M, Couture J, Dupont A, Cusan L & Labrie F 1988 Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate 12 79-84.
4. Bentel JM & Tilley WD 1996 Androgen receptors in prostate cancer. Journal of Endocrinology 151 1-11.
5. Blackledge GRP 1993 'Casodex': Mechanism of action and opportunities for usage. Cancer 72 (Suppl) 3830-3833.
6. Blackledge GRP, Cockshott ID & Furr BJA 1997 'Casodex' (bicalutamide): Overview of a new antiandrogen developed for the treatment of prostate cancer. European Urology 31 (Suppl 2) 30-39.
7. Chandolia RK, Weinbauer GF, Behre HM & Nieschlag E 1991 Evaluation of a peripherally selective antiandrogen ('Casodex') as a tool in studying the relationship between testosterone and spermatogenesis in the rat. Journal of Steroid Biochemistry and Molecular Biology 38 367-375.
8. Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ & Denis L 1990 The pharmacokinetics of 'Casodex' in prostate cancer patients after single and during multiple dosing. European Urology 18 (Suppl 3) 10-17.
9. Cockshott ID, Plummer GF, Cooper KJ & Warwick MJ 1991 The pharmacokinetics of 'Casodex' in laboratory animals. Xenobiotica 21 1347-1355.
10. Cockshott ID, Sotaniemi EA, Cooper KJ & Jones DC 1993 The pharmacokinetics of 'Casodex' enantiomers in subjects with impaired liver function. British Journal of Clinical Pharmacology 36 339-343.
11. Darbre PD & King RJB 1990 Antiandrogen ICI 176,334 does not prevent development of androgen insensitivity in S115 mouse mammary tumour cells. Journal of Steroid Biochemistry 36 385-389.
12. Dupont A, Gomez JC, Cusan L, Koutsilieris M & Labrie F 1993 Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. Journal of Urology 150 908-913.
13. Furr BJA 1996 Casodex: Preclinical studies. In Antiandrogens in Prostate Cancer, pp 75-88. Ed L Denis. Berlin: European School of Oncology Monograph, Springer.
14. Furr B JA & Tucker H 1996 The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47 (Suppl 1A) 13-25.
15. Gromoll J, Weinbauer GF, Simoni M & Nieschlag E 1993 Effects of antiandrogens and ethane dimethane sulphonate (EDS) on gene expression, free subunits, bioactivity and secretion of pituitary gonadotrophins in male rats. Molecular and Cellular Endocrinology 91 119-125.
16. Kelly WK & Scher H 1993 Prostatic specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. Journal of Urology 149 607-609.
17. Kemppainen JA & Wilson EM 1996 Agonist and antagonist actitivies of hydroxy flutamide and 'Casodex' relate to androgen receptor stabilization. Urology 48 157-163.
18. Labrie F, Dupont A & Belanger A 1985 Complete androgen blockade for the treatment of prostate cancer. In Important Advances in Oncology, pp 193-217. Eds VT de Vita, S Hellman & SA Rosenberg. Philadelphia: JB Lippincott.
19. Luo S, Martel C, Le Blanc G, Candas B, Singh SM, Labrie C, Simard J, Belanger A & Labrie F 1996 Relative potencies of Flutamide and Casodex: preclinical studies. Endocrine-Related Cancer 3 229-241.
20. McLeod DG 1997 The toxicity of antiandrogens. The Urologist (In Press).
21. Maucher A & Von Angerer E 1993 Antiproliferative activity of 'Casodex' (ICI 176,334) in hormone-dependent tumours. Journal of Cancer Research and Clinical Oncology 119 669-674.
22. Moguilewsky M, Fiet J, Tournemine C & Raynaud JP 1987 Pharmacology of an antiandrogen, Anandron, used as an adjuvant therapy in the treatment of prostate cancer. Journal of Steroid Biochemistry 24 139-146.
23. Mukherjee A, Kirkovsky L, Yao XT, Yates RC, Miller DD & Dalton JT 1996 Enantioselective binding of 'Casodex' to the androgen receptor. Xenobiotica 26 117-122.
24. Neri RO & Monahan M 1972 Effects of a novel nonsteroidal antiandrogen on canine prostatic hyperplasia. Investigative Urology 10 123-130.
25. Neri R, Florance K, Koziol P & Van Cleave S 1972 A biological profile of a nonsteroidal antiandrogen SCH 13521 (4′-nitro-3′-trifluoromethyl iso-butyranilide). Endocrinology 91 427-437.
26. Oncologic Drugs Advisory Committee 1983 Proceedings of the FDA Oncologic Drugs Advisory Committee, 25 March 1993. Rockville, MD, USA.
27. Radwanski E, Perentesis G, Symchowicz S & Zampaglione N 1989 Single and multiple dose pharmacokinetic evaluation of flutamide in normal and geriatric volunteers. Journal of Clinical Pharmacology 29 554-558.
28. Schellhammer P, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y & Kolvenbag GJCM 1996 A controlled trial of bicalutimide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Cancer 78 2164-2169.
29. Shunsuke K, Chieko S, Eri I & Hisao E 1995 Hormonal effects of a non-steroidal antiandrogenic drug, flutamide, and its active metabolite. Clinical Report 29 31-39.
30. Snyder BW, Winneker RC & Batzold FH 1989 Endocrine profile of WIN 49596 in the rat: a novel androgen receptor antagonist. Journal of Steroid Biochemistry 33 1127-1132.
31. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S & Shimazaki J 1996 Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29 153-158.
32. Teutsch G, Goubet F, Battmann J, Bonfils A, Bouchoux F, Cerede E, Gofflo D, Gaillard-Kelly M & Philibert D 1994 Non-steroidal antiandrogens: synthesis and biological profile of high affinity ligands for the androgen receptor. Journal of Steroid Biochemistry 48 111-119.
33. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA & Mulder E 1992 Antiandrogens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat shock protein interaction and transcription activation. Biochemistry 31 2393-2399.
34. Winneker RC, Wagner MM & Batzold FH 1989 Studies on the mechanism of action of WIN 45,596: a steroidal androgen receptor antagonist. Journal of Steroid Biochemistry 33 1133-1138.